Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of DWJ1351 (Olomax) vs Sevikar + Crestor in Healthy Males
NCT02665832Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of OLOMAX in hypertension (HTN) and hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Status: unknown.
02
Drugs
OLOMAX
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02665832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665832.